Log in

Orchard Therapeutics Stock Forecast, Price & News

0.00 (0.00 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $5.17
50-Day Range
MA: $5.18
52-Week Range
Now: $5.17
Volume496,131 shs
Average Volume570,082 shs
Market Capitalization$502.85 million
P/E RatioN/A
Dividend YieldN/A
Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. Its commercial stage products include Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-201 for mucopolysaccharidosis type IIIA and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Ltd. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:ORTX



Sales & Book Value

Annual Sales$2.51 million
Book Value$3.11 per share


Net Income$-163,420,000.00


Market Cap$502.85 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
0.00 (0.00 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ORTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ORTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Orchard Therapeutics (NASDAQ:ORTX) Frequently Asked Questions

How has Orchard Therapeutics' stock price been impacted by COVID-19?

Orchard Therapeutics' stock was trading at $9.08 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ORTX stock has decreased by 43.1% and is now trading at $5.17.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Orchard Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Orchard Therapeutics

When is Orchard Therapeutics' next earnings date?

Orchard Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Orchard Therapeutics

How were Orchard Therapeutics' earnings last quarter?

Orchard Therapeutics PLC - (NASDAQ:ORTX) announced its quarterly earnings results on Thursday, August, 6th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.05. The business had revenue of $0.60 million for the quarter.
View Orchard Therapeutics' earnings history

What price target have analysts set for ORTX?

3 Wall Street analysts have issued twelve-month price objectives for Orchard Therapeutics' stock. Their forecasts range from $16.00 to $28.00. On average, they anticipate Orchard Therapeutics' share price to reach $20.33 in the next twelve months. This suggests a possible upside of 293.3% from the stock's current price.
View analysts' price targets for Orchard Therapeutics

Are investors shorting Orchard Therapeutics?

Orchard Therapeutics saw a increase in short interest in August. As of August 31st, there was short interest totaling 2,670,000 shares, an increase of 35.5% from the August 15th total of 1,970,000 shares. Based on an average trading volume of 972,100 shares, the short-interest ratio is presently 2.7 days. Currently, 3.2% of the company's stock are sold short.
View Orchard Therapeutics' Short Interest

Who are some of Orchard Therapeutics' key competitors?

What other stocks do shareholders of Orchard Therapeutics own?

Who are Orchard Therapeutics' key executives?

Orchard Therapeutics' management team includes the following people:
  • Mr. Mark A. Rothera, CEO, Pres & Director (Age 56)
  • Dr. Anne Dupraz-Poiseau, Chief Regulatory Officer
  • Mr. Frank E. Thomas, CFO & Chief Bus. Officer (Age 49)
  • Ms. Ran Zheng, Chief Technical Officer
  • Prof. Bobby Gaspar Ph.D., M.D., Chief Scientific Officer, Director & Member of Scientific Advisory Board (Age 54)

When did Orchard Therapeutics IPO?

(ORTX) raised $200 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Orchard Therapeutics' stock symbol?

Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX."

Who are Orchard Therapeutics' major shareholders?

Orchard Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Deerfield Management Company L.P. Series C (7.46%), CHI Advisors LLC (3.01%), CHI Advisors LLC (3.01%), Federated Hermes Inc. (2.76%), Regents of The University of California (0.88%) and ArrowMark Colorado Holdings LLC (0.45%).
View institutional ownership trends for Orchard Therapeutics

Which major investors are selling Orchard Therapeutics stock?

ORTX stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, ArrowMark Colorado Holdings LLC, Driehaus Capital Management LLC, CHI Advisors LLC, CHI Advisors LLC, Artal Group S.A., Nuveen Asset Management LLC, and Two Sigma Advisers LP.
View insider buying and selling activity for Orchard Therapeutics

Which major investors are buying Orchard Therapeutics stock?

ORTX stock was purchased by a variety of institutional investors in the last quarter, including Regents of The University of California, Federated Hermes Inc., Platinum Investment Management Ltd., California Public Employees Retirement System, Goldman Sachs Group Inc., Mutual of America Capital Management LLC, Marshall Wace LLP, and Trexquant Investment LP.
View insider buying and selling activity for Orchard Therapeutics

How do I buy shares of Orchard Therapeutics?

Shares of ORTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Orchard Therapeutics' stock price today?

One share of ORTX stock can currently be purchased for approximately $5.17.

How big of a company is Orchard Therapeutics?

Orchard Therapeutics has a market capitalization of $502.85 million and generates $2.51 million in revenue each year. The company earns $-163,420,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. Orchard Therapeutics employs 180 workers across the globe.

What is Orchard Therapeutics' official website?

The official website for Orchard Therapeutics is www.orchard-tx.com.

How can I contact Orchard Therapeutics?

Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The company can be reached via phone at 011-44-0-203-3846700.

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.